Transcriptomic, proteomic, and lipidomic approaches also identified a novel druggable target for AML that exploits the regulation of fatty acid oxidation by the mitochondrial deacetylase, Sirtuin-3 (SIRT3). Here, SIRT3 is linked to acute myeloid leukemia.